logo-loader
Acasti Pharma Inc

Acasti Pharma awarded $750K by Canadian government to help develop flagship drug candidate CaPre

The financial support from the National Research Council of Canada Industrial Research Assistance Program will allow the company to expand and enhance its production capabilities for CaPre

Acasti Pharma Inc - Acasti Pharma Inc awarded $750,000 by Canadian government to help further develop its flagship prescription drug candidate CaPre designed to combat severe hypertriglyceridemia
CaPre is designed to combat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis

Acasti Pharma Inc (CVE:ACST) (NASDAQ:ACST) announced Monday that the Canadian government will give the company $750,000 to help further develop its flagship prescription drug candidate CaPre.

In a statement, the biopharmaceutical company said the support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) will allow it to expand and enhance its production capabilities for CaPre. 

The drug is designed to combat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis.

READ: Acasti Pharma says on track to release new CaPre trial results by end of 2019 after fruitful 1Q

CaPre is an omega-3 phospholipid concentrate derived from krill oil. The new treatment is currently being tested in the third phase of the TRILOGY clinical trials.

“We appreciate the strong support from NRC IRAP since 2015 and we are honored to embark on a new research and development project with them,” said Dr Pierre Lemieux, Acasti’s co-founder and chief operating and scientific officer.

“As we progress toward reporting our TRILOGY topline results, which we anticipate later this year, ramping up our commercial production capabilities is an important next step.”

Both Phase 1 and 2 TRILOGY studies achieved 100% patient randomization, and 68% of the patients have now completed their 6-month plan, Acasti told investors recently. 

The Laval, Quebec-based company expects Phase 1 results to be released by December 2019 followed by Phase 2 in January 2020.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: Acasti Pharma Inc

Price: $2.78

Market: TSX-V
Market Cap: $235.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Acasti Pharma receives $750,000 grant from National Research...

Acasti Pharma (CVE: ACST) Co-founder COO and Chief Scientific Officer Dr, Pierre Lemieux joined Steve Darling from Proactive Vancouver on Skype to discuss the company has received a sizable grant from the Canadian Government to help their drug development work. Lemieux telling Proactive what...

2 weeks ago

2 min read